Literature DB >> 1846502

The major and minor group receptor families contain all but one human rhinovirus serotype.

C R Uncapher1, C M DeWitt, R J Colonno.   

Abstract

Previous studies have assigned 88 human rhinovirus (HRV) serotypes to major and minor receptor groups. Extension of these studies to include the remaining 14 unassigned serotypes indicated that 13 serotypes belong to the major group since their infection of HeLa cells is completely blocked by a monoclonal antibody that recognizes the major group receptor. This result indicates that the major group now accounts for 91 of the 102 known serotypes, while the minor group contains 10 serotypes. One serotype, HRV-87, appears to utilize neither the major nor minor group receptor and may represent a third receptor group. HRV-87 attachment cannot be blocked by other serotypes and displays a binding tropism similar to but distinct from minor group viruses. Unlike major and minor group serotypes, HRV-87 attachment and infection requires the presence of sialic acid on cellular receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846502     DOI: 10.1016/0042-6822(91)90098-v

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  93 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Viral evolution toward change in receptor usage: adaptation of a major group human rhinovirus to grow in ICAM-1-negative cells.

Authors:  A Reischl; M Reithmayer; G Winsauer; R Moser; I Gösler; D Blaas
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Improved detection of rhinoviruses by nucleic acid sequence-based amplification after nucleotide sequence determination of the 5' noncoding regions of additional rhinovirus strains.

Authors:  K Loens; M Ieven; D Ursi; C De Laat; P Sillekens; P Oudshoorn; H Goossens
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  Sequence and structure of human rhinoviruses reveal the basis of receptor discrimination.

Authors:  Marketa Vlasak; Soile Blomqvist; Tapani Hovi; Elizabeth Hewat; Dieter Blaas
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 5.  Clinical and molecular features of human rhinovirus C.

Authors:  Yury A Bochkov; James E Gern
Journal:  Microbes Infect       Date:  2012-01-12       Impact factor: 2.700

6.  Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis.

Authors:  Marianne Brabec; Daniela Schober; Ernst Wagner; Nora Bayer; Robert F Murphy; Dieter Blaas; Renate Fuchs
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Recombinant VP4 of human rhinovirus induces permeability in model membranes.

Authors:  Matthew P Davis; Graham Bottley; Lucy P Beales; Richard A Killington; David J Rowlands; Tobias J Tuthill
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

Review 8.  Strategies for the identification of icosahedral virus receptors.

Authors:  D M Bass; H B Greenberg
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

9.  Molecular basis for the acid-initiated uncoating of human enterovirus D68.

Authors:  Yue Liu; Ju Sheng; Arno L W van Vliet; Geeta Buda; Frank J M van Kuppeveld; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

10.  Capsid region involved in hepatitis A virus binding to glycophorin A of the erythrocyte membrane.

Authors:  Glòria Sánchez; Lluís Aragonès; M Isabel Costafreda; Enric Ribes; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.